info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2032.


ID: MRFR/HC/5482-CR | 124 Pages | Author: Kinjoll Dey| December 2018
Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 21

3.2 Scope of the Study 21

3.3 Research Objective 21

3.4 Assumptions & Limitations 21

3.4.1 Assumptions 21

3.4.2 Limitations 21

3.5 Market Structure 22

4 Research Methodology

4.1 Research Process 24

4.2 Primary Research 25

4.3 Secondary Research 26

4.4 Market Size Estimation 27

4.5 Forecast Model 27

5 Market Dynamics

5.1 Introduction 29

5.2 Drivers 30

5.2.1 Rising prevalence of autoimmune diseases 30

5.2.2 Increasing research and development related to plasma-derived medicines 30

5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 30

5.3 Restraints 31

5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment 31

5.3.2 High cost of the IVIG treatment 31

5.4 Opportunity 31

5.4.1 Advancements in the treatment 31

5.5 Clinical Trials Data 32

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 34

6.1.1 Bargaining Power of Suppliers 34

6.1.2 Bargaining Power of Buyers 34

6.1.3 Threat of New Entrants 35

6.1.4 Threat of Substitutes 35

6.1.5 Intense Rivalry 35

6.2 Supply Chain Analysis 36

6.2.1 R&D and Designing 36

6.2.2 Manufacturing 36

6.2.3 Distribution & Sales 36

6.2.4 Post-Sales Monitoring 36

7 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

7.1 Introduction 38

7.2 Treatment 41

7.3 Diagnosis 41

8 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

8.1 Introduction 43

8.2 Intravenous 44

8.3 Oral 44

9 Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

9.1 Introduction 46

9.2 Hospitals 47

9.3 Specialty Neurological Clinics 47

9.4 Research & Academic Laboratories 48

10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region

10.1 Introduction 50

10.2 Americas 52

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1 North America 55

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1.1 U.S. 57

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1.2 Canada 59

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.2 South America 61

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3 Europe 64

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1 Western Europe 67

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.1 Germany 70

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.2 France 72

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.3 U.K 74

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.4 Italy 76

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.5 Spain 78

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.6 Rest of Western Europe 80

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.2 Eastern Europe 82

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4 Asia Pacific 84

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.1 China 87

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.2 Japan 89

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.3 India 91

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.4 Australia 93

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.5 Republic of Korea 95

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.6 Rest of Asia Pacific 97

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5 Middle East and Africa 99

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5.1 Middle East 102

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5.2 Africa 104

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

11 Competitive Landscape

11.1 Company Market Share Analysis 107

11.2 Introduction 107

12 Company Profiles

12.1 Grifols 110

12.1.1 Company Overview 110

12.1.2 Financial Overview 110

12.1.3 Products/Services Offered 111

12.1.4 SWOT Analysis 111

12.1.5 Key Developments 111

12.1.6 Key strategy 111

12.2 Shire 112

12.2.1 Company Overview 112

12.2.2 Financial Overview 112

12.2.3 Products/Services Offered 113

12.2.4 SWOT Analysis 113

12.2.5 Key Developments 113

12.2.6 Key strategy 113

12.3 Baxter 114

12.3.1 Company Overview 114

12.3.2 Company Overview 114

12.3.3 Products/Services Offered 115

12.3.4 SWOT Analysis 115

12.3.5 Key Developments 115

12.3.6 Key strategy 115

12.4 Pfizer, Inc. 116

12.4.1 Company Overview 116

12.4.2 Financial Overview 116

12.4.3 Products/Services Offered 117

12.4.4 SWOT Analysis 117

12.4.5 Key Developments 117

12.4.6 Key Strategy 117

12.5 CSL Behring 118

12.5.1 Company Overview 118

12.5.2 Financial Overview 118

12.5.3 Products/Services Offered 119

12.5.4 SWOT Analysis 119

12.5.5 Key Developments 119

12.5.6 Key Strategy 120

12.6 Kedrion S.p.A 121

12.6.1 Company Overview 121

12.6.2 Financial Overview 121

12.6.3 Products/Services Offered 122

12.6.4 SWOT Analysis 122

12.6.5 Key Development 122

12.6.6 Key Strategy 122

12.7 Octapharma 123

12.7.1 Company Overview 123

12.7.2 Financial Overview 123

12.7.3 Products/Services Offered 123

12.7.4 SWOT Analysis 124

12.7.5 Key Development 124

12.7.6 Key Strategy 124

12.8 Momenta Pharmaceuticals 125

12.8.1 Company Overview 125

12.8.2 Financial Overview 125

12.8.3 Products/Services Offered 126

12.8.4 SWOT Analysis 126

12.8.5 Key Development 126

12.8.6 Key Strategy 126

12.9 Teijin Pharma Limited 127

12.9.1 Company Overview 127

12.9.2 Financial Overview 127

12.9.3 Products/Services Offered 128

12.9.4 SWOT Analysis 128

12.9.5 Key Developments 128

12.9.6 Key strategy 128

12.10 Mitsubishi Tanabe Pharma Corporation 129

12.10.1 Company Overview 129

12.10.2 Financial Overview 129

12.10.3 Products/Services Offered 130

12.10.4 SWOT Analysis 130

12.10.5 Key Developments 130

12.11 Bio Products Laboratory Ltd. 131

12.11.1 Company Overview 131

12.11.2 Financial Overview 131

12.11.3 Products/Services Offered 131

12.11.4 SWOT Analysis 131

12.11.5 Key Developments 131

12.11.6 Key strategy 131

13 Appendix

13.1 Discussion Blue Print 133

14 List of Tables

TABLE 1 MARKET SYNOPSIS 19

TABLE 2 PRIMARY INTERVIEWS 24

TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 39

TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 40

TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 40

TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 40

TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION,

2020-2027 (USD MILLION) 41

TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION,

2020-2027 (USD MILLION) 41

TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 44

TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRAVENOUS BY REGION,

2020-2027 (USD MILLION) 44

TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION,

2020-2027 (USD MILLION) 44

TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2020-2027 (USD MILLION) 47

TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION,

2020-2027 (USD MILLION) 47

TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS,

BY REGION, 2020-2027 (USD MILLION) 47

TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC

LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 51

TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 52

TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 52

TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 53

TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 53

TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 53

TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 54

TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 54

TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 55

TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 55

TABLE 26 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 55

TABLE 27 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 56

TABLE 28 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 56

TABLE 29 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 56

TABLE 30 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 57

TABLE 31 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 57

TABLE 32 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 57

TABLE 33 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 58

TABLE 34 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 58

TABLE 35 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 58

TABLE 36 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 59

TABLE 37 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 59

TABLE 38 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 59

TABLE 39 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 60

TABLE 40 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 60

TABLE 41 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 60

TABLE 42 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 61

TABLE 43 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 61

TABLE 44 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 61

TABLE 45 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 62

TABLE 46 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 62

TABLE 47 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 62

TABLE 48 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 63

TABLE 49 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 64

TABLE 50 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 64

TABLE 51 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 65

TABLE 52 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 65

TABLE 53 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 65

TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 66

TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 66

TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 67

TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 67

TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 69

TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 69

TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 70

TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 70

TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 70

TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 71

TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 71

TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 71

TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 72

TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

\2020-2027 (USD MILLION) 72

TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 72

TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 73

TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 73

TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 73

TABLE 75 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 74

TABLE 76 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 74

TABLE 77 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 74

TABLE 78 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 75

TABLE 79 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 75

TABLE 80 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 75

TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 76

TABLE 82 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 83 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 84 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 77

TABLE 85 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 77

TABLE 86 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 77

TABLE 87 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 78

TABLE 88 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 78

TABLE 89 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 78

TABLE 90 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 79

TABLE 91 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 79

TABLE 92 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 79

TABLE 93 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 80

TABLE 94 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

TREATMENT BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 95 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

DIAGNOSIS BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 96 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 81

TABLE 97 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 81

TABLE 98 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 81

TABLE 99 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 82

TABLE 100 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 101 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 102 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 103 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 83

TABLE 104 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 83

TABLE 105 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 84

TABLE 106 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 84

TABLE 107 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 85

TABLE 108 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 85

TABLE 109 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 110 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 86

TABLE 111 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 86

TABLE 112 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 87

TABLE 113 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 87

TABLE 114 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 87

TABLE 115 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 88

TABLE 116 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 88

TABLE 117 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 88

TABLE 118 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 89

TABLE 119 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 89

TABLE 120 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 89

TABLE 121 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 90

TABLE 122 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 90

TABLE 123 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 90

TABLE 124 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 91

TABLE 125 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 91

TABLE 126 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 91

TABLE 127 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 128 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 92

TABLE 129 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 92

TABLE 130 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 93

TABLE 131 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 93

TABLE 132 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 93

TABLE 133 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 134 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 94

TABLE 135 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 94

TABLE 136 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 95

TABLE 137 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 138 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 95

TABLE 139 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 140 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 96

TABLE 141 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 96

TABLE 142 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 97

TABLE 143 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 144 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 145 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 98

TABLE 146 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 98

TABLE 147 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 98

TABLE 148 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION,

2020-2027 (USD MILLION) 99

TABLE 149 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 99

TABLE 150 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 151 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 152 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 153 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 101

TABLE 154 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 101

TABLE 155 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 102

TABLE 156 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 157 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 158 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 103

TABLE 159 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 103

TABLE 160 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 103

TABLE 161 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 104

TABLE 162 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 104

TABLE 163 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 104

TABLE 164 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 105

TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 105

TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 105

15 List of Figures

FIGURE 1 RESEARCH PROCESS 24

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH 27

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

(CIDP) MARKET 29

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 34

FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 36

FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS,

2020 (%) 39

FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020 & 2027 (USD MILLION) 39

FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF

ADMINISTRATION, 2020 (%) 43

FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020 & 2027 (USD MILLION) 43

FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2020 (%) 46

FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2020 & 2027 (USD MILLION) 46

FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 50

FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 52

FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 64

FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 67

FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 84

FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE,

BY COUNTRY, 2020 (%) 99

FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2020 (%) 107

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.